| ESMO: Mirati pulls away from Amgen in colorectal cancer with rival KRAS drug Q&A: Eli Lilly is making strides in overall trial diversity, but oncology lags behind Bankrolled by Pfizer and Bayer, Pyxis files for $100M IPO to take cancer drugs into the clinic Sponsored: What’s Driving Record Capital in Genetic Medicine? Sanofi-backed Jeito Capital closes $630M fund to finance 12-15 European biopharmas Sponsored: A New Reference Model for Clinical Trial Recruitment, Enrollment and Retention Success Mirati switches up leadership as KRAS drug speeds toward FDA filing Gubra strikes $253M biobucks deal with Bayer on heart, kidney disorder treatments New insights into bats' immunity could point to therapeutic approaches for fighting COVID-19 Hong Kong COVID tester Prenetics sets up $1.7B SPAC deal ESMO: In landmark win, Novartis' Kisqali extends breast cancer survival by one year. Can it challenge Pfizer's Ibrance? HHS announces funds, legal protections for abortion providers and patients SPAC Attack: The 10 biggest in healthcare Featured Story | By Nick Paul Taylor Mirati Therapeutics has spent 2021 watching Amgen blast past it to win the race to bring a KRAS drug to market in lung cancer. Yet, with Amgen’s Lumakras underwhelming in colorectal cancer, Mirati still has a shot at carving out a niche. The small biotech rocked up to this year’s European Society of Medical Oncology congress with data to make its case. read more |
| |
|---|
|
Top Stories By Annalee Armstrong Eli Lilly has made strides in increasing the diversity of clinical trials overall, but when you zoom in on oncology, people of color continue to be left out. read more By Nick Paul Taylor Pyxis Oncology is aiming to close out a transformative 2021 with an IPO. Having licensed a pair of antibody-drug conjugates from Pfizer and raised a megaround to develop them, Pyxis is now seeking to tap public investors for cash in an IPO filing that sets the initial fundraising target at $100 million. read more Sponsored By: RBC Capital Markets Gene editing is at the new frontier of biotech innovation, driving capital investments and momentum within the IPO market. Learn more. read more By Kyle LaHucik Paris-based private equity firm Jeito Capital has closed its first fund at $630 million, with an investor list including Sanofi and Temasek, to help finance 12 to 15 European biopharmas. read more Sponsored by: IPM.ai Rare diseases demand a modern recruitment approach grounded in uncovering the ideal, medically-eligible patient population with the highest propensity for study enrollment and retention. read more By Kyle LaHucik Mirati is gearing up to move a hotly anticipated KRAS inhibitor to regulatory filings, and now the biotech will have a new industry veteran at the helm to complete the work. read more By Kyle LaHucik Bayer will pay up to $253 million in biobucks to use Gubra's machine learning drug discovery tools to find potential treatments for kidney and heart disorders. read more By Kyle LaHucik Knowing that bats can ward off many coronaviruses better than humans can, researchers at Monash University reviewed studies of the animal's immune responses to SARS-CoV-2, the virus behind COVID-19. Their findings could lead to new strategies for fighting the disease, such as reducing inflammasome signaling, they suggested. read more By Conor Hale The proceeds will fund Prenetics' global expansion as well as an acquisition strategy aimed at growing its U.S. footprint. read more By Angus Liu Novartis’ breast cancer drug Kisqali already has two clinical wins under its belt showing a survival benefit over traditional treatment. Now, the company hopes a third, first-of-its-kind victory in newly diagnosed patients could give it a better shot at challenging Pfizer’s market-leading Ibrance. But a shift may not be up to the Swiss pharma. read more By Anastassia Gliadkovskaya The department’s announcement Friday included a list of planned actions like grant support for clinics and legal protections for healthcare workers and pregnant patients. Following passage of Texas’ Senate Bill 8, otherwise known as the "heartbeat bill," the Biden administration has directed a number of government agencies, including HHS, to find ways to safeguard reproductive rights for Texans. read more By Heather Landi Spurred by the COVID-19 pandemic and the virtual care boom, special purpose acquisition companies have been on a red-hot streak, triggering a whirlwind of public exit activity for healthcare and digital health startups. read more | | Download the AppNote to learn about Thermo Fisher Scientific’s GMP-compliant, semiautomated manufacturing platform, which when used with Gibco CTS reagents, protocols, and analytics can result in consistent, efficacious CAR T cell production. Download Now. |
Resources Sponsored By: Unlearn AI Read Unlearn’s whitepaper to learn about how novel trial designs with Digital Twins enable more efficient clinical trials, with higher power and smaller required sample sizes. Sponsored by: Patheon by Thermo Fisher Scientific Choose the right AAV platform for your viral vector-based therapy Sponsored by: XIFIN inc. Download the Value of Precision Medicine Informatics (PMI) Initiatives report to learn about the technology, data types, and the value derived from more than 100 PMI initiatives. Sponsored by: EVERSANA Today’s economics do not allow manufactures to keep making decisions in an antiquated way. They need to challenge tradition & deliver faster, cheaper, successful launches. Learn how. Sponsored by: Thermo Fisher Scientific Thermo Fisher Scientific introduces a new NK cell culture medium designed to support feeder-free, high-yield growth for cell therapy applications. Sponsored by: Cascade Chemistry by Aceto Read four customer success stories and four success factors that helped move pharmaceutical customers of Cascade Chemistry by Aceto quickly and effectively to clinic with trial-ready APIs. Sponsored by: ConnectiveRx Topple barriers to getting patients started on therapy. Guide them with mobile. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Let A Digital Sherpa Uncomplicate The Path for Patients Wednesday, September 15 | 1 PM ET Sea-dumped chemical weapons: environmental risk, occupational hazard September 22, 2021 1pm EST Clinical Quality Oversight Forum September 27-29, 2021 | Philadelphia, PA The MedTech Conference 2021 September 27 - 30, 2021 Introduction to Structure Elucidation in Drug Development Sep 29, 2021 1 pm EST Pharma PR & Communications Summit October 4-5, 2021 | Jersey City, NJ Virtual U.S. Healthcare Compliance Certificate Program October 11 – 14, 2021 Fierce Biotech Cell & Gene Therapy October 19, 2021 | Virtual Event Fierce Health Payer Summit October 26, 2021 | Virtual Event Announcing the 9th International mRNA Health Conference November 09-10, 2021 | Mercure MOA Berlin & Online Diversity, Equity & Inclusion Week November 9–11, 2021 | Virtual Event Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. Fierce Biotech Forum 2022 | Virtual Event | 